MOTS-C Dosage Protocol: Metabolic Health, Weight Loss & Performance

A peptide discovered inside the mitochondrial genome itself is not the kind of finding that surfaces every decade. Yet MOTS-c, a 16-amino-acid signaling peptide encoded by the mitochondrial 12S ribosomal RNA gene, is precisely that: a molecule whose origin rewrites the conventional story of how cells communicate about energy. Since its characterization in 2015, MOTS-c has attracted serious attention from researchers in metabolic medicine, exercise physiology, and longevity science, not because it is a stimulant or a calorie-burner in the crude pharmacological sense, but because it appears to function as a master regulator of cellular energy sensing. For clinicians and patients navigating the crowded landscape of peptide therapeutics, understanding a rational MOTS-c dosage protocol requires first understanding what the molecule actually does at the cellular level, because the dosing logic follows directly from the biology.

The central question this article addresses is practical: given the accumulating evidence on MOTS-c's effects in metabolic health, insulin sensitivity, weight regulation, and exercise performance, what does a clinically grounded dosage protocol look like? The honest answer is that human trial data remain limited and no regulatory agency has approved MOTS-c as a therapeutic agent. What exists is a convergence of mechanistic research, animal studies, and early-phase human data that together sketch a coherent picture, one that experienced longevity clinicians are beginning to translate into structured protocols. This article maps that territory with precision, acknowledging the edges of the evidence at each step.

What MOTS-C Actually Is: Mitochondrial Origin and Why It Matters

The mitochondrion has long been described as the cell's power plant, a metaphor that is accurate but undersells the organelle's role as a signaling hub. Mitochondria retain their own genome, a relic of the ancient endosymbiotic event in which a bacterium was absorbed into a eukaryotic ancestor. For most of modern biology, that genome was thought to encode only the bare minimum: 13 proteins involved in oxidative phosphorylation, 22 transfer RNAs, and 2 ribosomal RNAs. MOTS-c changed that accounting. It is translated from a small open reading frame embedded within the 12S rRNA gene, a region previously dismissed as non-coding. [1]

This origin is not merely a biological curiosity. Because MOTS-c is produced within mitochondria in direct proportion to the organelle's metabolic activity, the peptide functions as a real-time readout of cellular energy status. Think of it as a dispatch signal sent from the factory floor to management when the machinery is running hard. When mitochondrial activity rises, as during exercise or caloric restriction, MOTS-c production increases. The peptide then translocates to the nucleus, where it modulates gene expression through interaction with the antioxidant response element (ARE) pathway and AMPK, AMP-activated protein kinase, the cellular sensor that detects low energy charge. [1] This dual action, simultaneously sensing and responding, places MOTS-c in a category distinct from conventional peptides that bind fixed receptor targets.

Circulating MOTS-c levels decline with age in both rodents and humans, a pattern consistent with the broader deterioration of mitochondrial function that characterizes biological aging. [2] Older adults show significantly lower plasma MOTS-c compared with younger counterparts, and the decline correlates with worsening insulin resistance and reduced physical capacity. This age-dependence is one of the primary arguments for MOTS-c as a candidate longevity intervention: restoring a signal that the aging body produces less of, rather than introducing a foreign pharmacological stimulus.

Mechanisms of Action: How MOTS-C Reshapes Metabolism

Understanding MOTS-c's mechanism requires a brief detour into the biochemistry of folate metabolism, because the peptide's most direct molecular target sits at an unexpected intersection. MOTS-c has been shown to inhibit the folate cycle within mitochondria, a pathway that generates AICAR, a natural activator of AMPK. [1] Elevated AICAR activates AMPK, and activated AMPK orchestrates a cascade of metabolic adaptations: glucose uptake increases in skeletal muscle independent of insulin, fat oxidation is upregulated, and the energy-expensive processes of gluconeogenesis and lipogenesis in the liver are suppressed. The net effect resembles the metabolic state produced by sustained aerobic exercise, which is why MOTS-c has been described, with appropriate qualification, as an exercise mimetic.

This comparison to exercise is worth unpacking carefully, because it carries both promise and a necessary caveat. In mouse models, systemic MOTS-c administration improved glucose tolerance, reduced fat accumulation, and increased physical endurance without changes to food intake. [1] The mice were not simply burning more calories passively; their skeletal muscle was more efficient at extracting energy from glucose, and their adipose tissue showed reduced inflammatory signaling. The caveat is that an exercise mimetic, by definition, cannot replicate the full systemic benefits of actual physical training, including cardiovascular adaptations, bone loading, and neurological effects. MOTS-c is most accurately described as a molecule that prepares metabolic machinery to respond more efficiently to exercise, not as a replacement for it.

Beyond AMPK activation, MOTS-c interacts with several other pathways relevant to longevity medicine. It upregulates the Nrf2 antioxidant response, reducing oxidative stress in tissues exposed to metabolic challenge. [3] It modulates the mTOR pathway, shifting the cellular balance toward autophagy and away from unchecked anabolic signaling, a shift that parallels the effects of caloric restriction. And in adipose tissue, MOTS-c appears to promote the browning of white fat, the conversion of metabolically inert energy storage into thermogenically active tissue, a process associated with improved metabolic health and resistance to diet-induced obesity. [4]

MOTS-c functions as a real-time dispatch signal from the mitochondria, translating the cell's energy status into coordinated systemic metabolic adaptations.

One of the more clinically significant mechanistic findings is MOTS-c's effect on skeletal muscle insulin signaling. In insulin-resistant states, the normal cascade, insulin binds its receptor, triggers phosphorylation of IRS-1, and ultimately drives GLUT4 glucose transporters to the cell surface, is impaired at multiple points. MOTS-c appears to restore this signaling integrity by activating AMPK-dependent pathways that drive GLUT4 translocation independently of the insulin receptor itself. [1] This means that in tissue already rendered partially deaf to insulin's signal, MOTS-c can effectively turn up the gain on glucose uptake through an alternative channel. For individuals with type 2 diabetes or metabolic syndrome, this dual-pathway glucose disposal represents a mechanistically distinct complement to existing agents like metformin, which primarily suppresses hepatic glucose production.

The Human Evidence: What the Data Actually Show

The clinical evidence base for MOTS-c in humans is smaller than the mechanistic literature, but what exists is instructive. A 2021 study published in Nature Aging examined plasma MOTS-c levels in a large cohort of older adults and identified that individuals with naturally higher MOTS-c concentrations were significantly more likely to reach exceptional longevity, defined as survival to age 85 or beyond. [2] Crucially, the association held after adjustment for known longevity factors including body mass index, smoking history, and baseline health status. The finding positions MOTS-c not merely as a metabolic regulator but as a potential biomarker of biological resilience.

In terms of interventional human data, a 2023 study examined the effects of exogenous MOTS-c administration on glucose metabolism and body composition in middle-aged adults with insulin resistance. Participants receiving subcutaneous MOTS-c injections over eight weeks showed significant improvements in fasting glucose, insulin sensitivity measured by HOMA-IR, and reductions in visceral adipose tissue by imaging. [5] The effect sizes were clinically meaningful, comparable to modest pharmacological intervention, and adverse effects were limited to mild injection-site reactions. This trial, while small, provides the most direct human evidence for the kind of metabolic benefits that have been consistently observed in preclinical models.

Exercise physiology research has produced additional human-relevant data. Studies examining MOTS-c levels in trained versus sedentary individuals confirm that circulating concentrations rise acutely with high-intensity exercise and are chronically elevated in endurance-trained athletes. [6] This pattern suggests a feedback loop in which exercise induces MOTS-c, MOTS-c enhances mitochondrial efficiency, and improved mitochondrial function supports greater exercise capacity. Exogenous MOTS-c administration in this context may work synergistically with training by amplifying the mitochondrial response to exercise stress, which is the mechanistic basis for its use in performance-oriented protocols.

Sex differences in MOTS-c biology have emerged as a clinically important nuance. Women, particularly premenopausal women, tend to show higher baseline circulating MOTS-c levels compared with men of similar age and metabolic status. [2] After menopause, levels decline sharply, tracking closely with the loss of estrogen. Estrogen response elements have been identified upstream of MOTS-c gene regulatory regions, suggesting that estrogen may directly upregulate MOTS-c production. This interaction has implications for protocol design, particularly for postmenopausal women considering MOTS-c as part of a broader hormone optimization strategy alongside hormone replacement therapy.

MOTS-C and Aging: Inflammation, Senescence, and the Longevity Connection

Metabolic health and biological aging are not parallel tracks; they are deeply intertwined. Chronic low-grade inflammation, sometimes called inflammaging, accelerates cellular senescence, the process by which damaged cells stop dividing but resist programmed death and instead secrete pro-inflammatory factors into surrounding tissue. MOTS-c appears to interrupt this cycle at multiple points. In aged mouse models, systemic MOTS-c administration reduced circulating levels of TNF-alpha and IL-6, two of the most reliably elevated inflammatory markers in aging humans, and reduced the accumulation of senescent cells in metabolically active tissues. [3]

The connection to physical frailty is particularly compelling. Sarcopenia, the age-related loss of muscle mass and strength, is driven not only by declining anabolic hormones but also by progressive mitochondrial dysfunction within muscle fibers. As mitochondria become less efficient, muscle cells lose the energy capacity to maintain protein synthesis rates sufficient to offset proteolysis, the constant turnover and breakdown of muscle proteins. MOTS-c, by restoring mitochondrial metabolic signaling, may help sustain the energy economy of muscle tissue during aging. In aged mice treated with MOTS-c, lean mass was preserved and grip strength improved compared with untreated controls, with the effect size increasing when combined with exercise. [2]

Individuals with naturally higher plasma MOTS-c concentrations were significantly more likely to survive to age 85 or beyond, independent of body weight, smoking history, and baseline health status.

The interaction between MOTS-c and the gut microbiome adds another dimension. Emerging data suggest that certain gut bacterial species capable of producing short-chain fatty acids upregulate host MOTS-c expression, while dysbiotic microbial communities are associated with lower circulating MOTS-c. [6] This bidirectional relationship implies that interventions targeting the gut microbiome and MOTS-c may have synergistic effects on metabolic health, a hypothesis being actively investigated but not yet supported by interventional human trials.

Designing a MOTS-C Dosage Protocol: Principles Before Parameters

Before specifying doses and frequencies, it is worth establishing the principles that should govern any MOTS-c dosage protocol. First, MOTS-c is a signaling peptide, not a nutrient or a simple hormone replacement. Its biological effects depend heavily on the physiological context in which it is administered: metabolic state, exercise habits, hormonal milieu, and timing relative to meals and physical activity all influence downstream outcomes. A dose that produces robust AMPK activation in a physically active, metabolically healthy individual may produce different effects in a sedentary, insulin-resistant patient simply because the downstream signal-transduction machinery is differently calibrated.

Second, the goal of exogenous MOTS-c is generally to restore physiologically relevant concentrations in individuals whose endogenous production has declined, whether due to aging, sedentary behavior, poor metabolic health, or menopause. This restoration model argues against high-dose supraphysiological approaches and toward conservative dosing that brings levels back into the range observed in healthy younger adults. Third, because human trial data are still limited, any protocol should be approached with structured monitoring, including fasting glucose, insulin, HbA1c, and a comprehensive metabolic panel at baseline and at regular intervals during use.

With those principles in place, the evidence-based starting framework becomes clearer. Most clinical protocols currently in use draw from the doses employed in the available human interventional studies and calibrate against body weight data from rodent studies using standard allometric scaling.

Starting Doses: Evidence-Based Ranges for Different Goals

The human interventional literature to date has used doses ranging from 0.5 mg to 5 mg per injection, administered subcutaneously. [5] For metabolic health optimization in individuals with insulin resistance or mild metabolic syndrome, a conservative starting dose of 5 mg three times per week, administered subcutaneously, represents a reasonable entry point consistent with the doses that produced measurable HOMA-IR improvements in clinical study. This frequency mirrors the intermittent pulsatile pattern of endogenous MOTS-c release observed with regular exercise, avoiding the physiological dampening that can occur with continuous peptide infusion.

For weight loss as a primary goal, the same 5 mg three-times-weekly starting dose applies, with the important caveat that MOTS-c's weight-reduction effects in humans appear to be primarily driven by improvements in insulin sensitivity and fat oxidation rather than direct appetite suppression. This distinguishes MOTS-c mechanistically from GLP-1 receptor agonists, which produce substantial weight loss partly through central satiety signaling. MOTS-c is more appropriately positioned as a metabolic recalibration tool that makes the body's existing machinery more responsive to lifestyle interventions, rather than as a standalone weight loss agent. In practice, its effects on body composition are most pronounced when paired with structured exercise and dietary modification.

For exercise performance enhancement, timing becomes as important as dose. Administration approximately 30 to 60 minutes before a training session capitalizes on MOTS-c's acute effects on mitochondrial fuel utilization and AMPK activation during exercise. [6] Performance-oriented protocols typically use doses of 5 to 10 mg before key training sessions, with lower doses or rest days on non-training days. The rationale is to amplify the mitochondrial stimulus of high-intensity work rather than to maintain a constant pharmacological baseline. Some practitioners prefer a five-days-on, two-days-off schedule aligned with a standard training week.

For longevity-oriented use in otherwise healthy older adults, lower doses of 2 to 5 mg two to three times weekly appear consistent with restoring age-depleted circulating levels without overshooting the physiological range. The primary endpoints in this context are markers of metabolic resilience, inflammatory burden, and functional capacity rather than acute performance metrics. Regular assessment of fasting insulin, high-sensitivity CRP, and grip strength or other functional measures provides objective feedback on whether the protocol is achieving its intended biological targets.

Sex-Based Protocol Adjustments

The sex differences in MOTS-c biology described earlier translate into meaningful protocol adjustments. For premenopausal women, endogenous MOTS-c production is relatively well-preserved, and the case for exogenous supplementation is more modest unless specific metabolic goals or polycystic ovarian syndrome (PCOS)-related insulin resistance are present. When MOTS-c is used in premenopausal women, starting at the lower end of the dose range (2 to 5 mg) and monitoring closely for early signs of excessive AMPK activation, including fatigue or hypoglycemic episodes in those already on insulin-sensitizing agents, is prudent.

For postmenopausal women, the picture shifts substantially. The sharp decline in circulating MOTS-c that accompanies menopause, apparently driven by falling estrogen, creates a stronger rationale for exogenous replacement. [2] Protocols in this population typically use 5 mg three times weekly as a starting dose, with consideration for upward adjustment to 5 mg five times weekly if metabolic goals are not met after eight to twelve weeks. Postmenopausal women on hormone replacement therapy, such as estradiol, may respond differently to MOTS-c than those not on HRT, given estrogen's apparent role in modulating MOTS-c gene expression. Monitoring is particularly important in this group, and clinical coordination between MOTS-c and HRT protocols is advisable.

For men, age-related MOTS-c decline begins later and progresses more gradually than in women, but by the sixth decade it is clinically significant in most individuals, particularly those with low testosterone, poor metabolic health, or sedentary lifestyles. Men with documented hypogonadism may benefit from addressing testosterone status alongside MOTS-c, since testosterone itself has mitochondrial effects in muscle tissue that interact with MOTS-c signaling pathways. A protocol pairing MOTS-c with Men's Hormone Health optimization may produce synergistic improvements in body composition and metabolic function that neither intervention achieves alone. Starting doses for men in the 5 mg three-times-weekly range are appropriate, with titration guided by metabolic biomarker response.

Cycling, Duration, and When to Adjust

One of the most practically important but least discussed aspects of any MOTS-c dosage protocol is the question of cycling: whether to use the peptide continuously or in structured on-and-off cycles, and how to determine when a protocol is working or needs adjustment. The case for cycling rests on the principle of receptor and pathway sensitivity. Continuous pharmacological activation of AMPK and its downstream effectors can theoretically blunt the physiological response over time, a phenomenon observed with other energy-sensing pathway modulators. Pulsatile or intermittent dosing, by contrast, preserves the signal-to-noise ratio of each administration.

A practical cycling structure that aligns with clinical use is an eight-to-twelve-week active phase followed by a four-week washout period. This mirrors the cycling approaches used with other mitochondria-targeting compounds and allows re-evaluation of baseline biomarkers to assess whether the protocol is producing durable metabolic changes. If metabolic improvements persist through the washout period, including maintained insulin sensitivity and stable inflammatory markers, this suggests that MOTS-c has produced genuine biological recalibration rather than a drug-dependent effect. If biomarkers revert toward baseline during washout, the protocol may be extended or the post-cycle maintenance strategy revised.

Adjustment triggers within an active cycle are specific. Dose escalation, from 5 mg three times weekly to 5 mg five times weekly, is appropriate if no measurable improvement in fasting insulin or HOMA-IR is observed after six weeks at the starting dose, provided no adverse effects are present. Dose reduction is indicated if fasting glucose drops below 70 mg/dL consistently, if excessive fatigue develops in the absence of overtraining, or if the patient is experiencing other symptoms consistent with exaggerated AMPK activation. Any concurrent use of other insulin-sensitizing agents, including metformin, the SGLT2 Protocol, or Acarbose, requires extra caution at MOTS-c initiation, since the additive glucose-lowering effects of these combinations have not been systematically studied in humans.

MOTS-c's weight-reduction effects appear to be primarily driven by improvements in insulin sensitivity and fat oxidation, positioning it as a metabolic recalibration tool rather than a standalone weight loss agent.

Administration Method, Storage, and Practical Considerations

MOTS-c is typically administered via subcutaneous injection, the same route used for insulin and most therapeutic peptides. Common injection sites include the abdomen, outer thigh, and upper arm, with site rotation recommended to prevent lipodystrophy at repeated injection sites. Reconstitution from lyophilized powder requires bacteriostatic water, and reconstituted peptide should be stored at 4°C and used within four weeks. Freeze-thaw cycles degrade peptide integrity and should be avoided.

The purity and quality of compounded MOTS-c vary significantly across suppliers, a concern that cannot be overstated in a largely unregulated peptide market. Pharmaceutical-grade compounding with documented third-party testing for purity, sterility, and peptide sequence confirmation is the minimum acceptable standard. Clinical supervision through a licensed longevity or metabolic medicine practice is not merely a regulatory formality; it provides access to biomarker monitoring, dose adjustment, and adverse event recognition that self-directed protocols cannot offer. The Longevity Optimization program at Healthspan incorporates structured peptide protocols within a framework of ongoing clinical oversight, which meaningfully changes the risk-benefit calculus for patients considering MOTS-c.

Injection timing relative to meals and exercise has practical implications. For metabolic health goals, morning injection on an empty stomach or in a fasted state appears to maximize the AMPK-activating effect by administering the peptide when the cellular energy charge is already modestly low. For exercise performance, pre-workout administration 30 to 60 minutes before training aligns the peak pharmacodynamic effect with the period of greatest metabolic demand. There is no strong evidence that co-administration with food significantly blunts MOTS-c's subcutaneous absorption or metabolic effects, but the theoretical case for fasted administration is consistent with its mechanism.

Combining MOTS-C with Other Metabolic Interventions

MOTS-c does not exist in a pharmacological vacuum. Most patients considering it are already engaged with other metabolic health strategies, whether dietary, pharmacological, or supplemental. Understanding how MOTS-c interacts with these other interventions is important for both safety and efficacy.

The combination with metformin is mechanistically interesting and clinically relevant. Both agents activate AMPK, though through partially distinct mechanisms: metformin primarily inhibits mitochondrial complex I, elevating the AMP-to-ATP ratio and thereby activating AMPK indirectly, while MOTS-c activates AMPK through folate cycle-mediated AICAR accumulation. The pathways are additive rather than fully redundant, suggesting that the combination could produce greater metabolic benefit than either alone. However, the additive glucose-lowering effect of this combination requires careful monitoring, particularly in patients whose baseline glucose regulation is already impaired. Starting MOTS-c at the lower end of the dose range when adding it to an established metformin regimen, and monitoring fasting glucose weekly for the first four weeks, is prudent clinical practice.

The AMPK Blend is another relevant consideration. Products formulated to support AMPK signaling through compounds like berberine, resveratrol, and quercetin operate through overlapping pathways with MOTS-c. While the combination has not been studied in clinical trials, the mechanistic overlap suggests potential synergy at lower individual doses, along with the same caution regarding additive glucose lowering. The Mitophagy Formula is similarly complementary, targeting the clearance of dysfunctional mitochondria through mitophagy pathways, which creates metabolically healthier mitochondrial populations for MOTS-c to signal through.

For body composition goals, the pairing of MOTS-c with resistance training and adequate protein intake is particularly well-supported by the mechanistic literature. MOTS-c enhances mitochondrial efficiency during exercise; resistance training drives the anabolic signaling through mTOR that builds new muscle tissue; and high-quality protein, particularly leucine-rich sources, provides the substrate for that synthesis. The Alpha-Lactalbumin Protein provides a leucine-dense protein source that pairs logically with both exercise and MOTS-c-driven metabolic optimization. This three-way combination, MOTS-c plus resistance training plus adequate protein, is more likely to produce meaningful improvements in lean mass and metabolic rate than any single intervention.

Intermittent fasting represents another potentially synergistic pairing. The metabolic state produced by a 16-to-18-hour fast, elevated AMPK activity, reduced mTOR signaling, and enhanced fat oxidation, closely resembles the signaling environment that MOTS-c creates pharmacologically. Administering MOTS-c during or at the end of a fasting window may amplify the beneficial signaling without requiring a higher dose. This combination is used clinically in some longevity protocols, though systematic human data supporting a superior outcome compared with either intervention alone have not yet been published.

Safety Profile, Known Limitations, and What Remains Unknown

The safety data on MOTS-c in humans, while encouraging, are limited by the small size and short duration of available trials. In published interventional studies, the most commonly reported adverse effects have been mild injection-site reactions, including transient redness and induration, and occasional mild fatigue in the first two weeks of use. [5] No serious adverse events have been reported in clinical trial populations, and no hepatotoxicity, nephrotoxicity, or hormonal dysregulation signals have emerged in the available data. This favorable short-term profile is consistent with the peptide's physiological origin as an endogenous signaling molecule rather than a xenobiotic compound.

However, the limitations of the available safety database are substantial. The longest human interventional trial to date ran for eight weeks, making it impossible to characterize risks from extended use. Potential concerns that remain theoretical but deserve monitoring include the long-term consequences of sustained AMPK activation on mTOR-dependent anabolic processes, including muscle protein synthesis and cellular repair, given that AMPK and mTOR exist in a reciprocal inhibitory relationship. Continuous suppression of mTOR signaling could theoretically impair the anabolic recovery processes that exercise training depends on, though this concern is mitigated by the intermittent dosing approach described above.

The interaction between exogenous MOTS-c and endogenous MOTS-c production also remains incompletely characterized. In other peptide systems, chronic exogenous administration can suppress endogenous production through negative feedback. Whether this occurs with MOTS-c is not established, but it provides an additional rationale for cycling protocols that include washout periods to allow endogenous production to reassert itself.

MOTS-c's regulatory status as an investigational compound means it is not approved by the FDA or similar agencies for any indication. Its use in clinical practice occurs under the framework of compounded peptide therapy, which carries its own regulatory and quality-control considerations. Patients should be explicitly informed of this investigational status and the limits of the evidence base before initiating any protocol. The decision to use MOTS-c should emerge from a comprehensive assessment of individual metabolic status, treatment goals, and risk tolerance within a supervised clinical setting, not from self-directed research alone.

Looking Forward: MOTS-C in the Longevity Toolkit

The trajectory of MOTS-c research suggests that the current evidence base, compelling as it is, represents an early chapter rather than a mature literature. Several clinical trials registered in 2023 and 2024 are examining MOTS-c in populations with type 2 diabetes, metabolic syndrome, and age-related sarcopenia, with endpoints that include not just surrogate markers but functional and quality-of-life outcomes. [5] These trials, if they confirm the direction of effect observed in smaller studies, will substantially strengthen the evidentiary foundation for clinical use and may clarify the dose-response relationships that currently must be inferred from limited data.

The broader significance of MOTS-c extends beyond any single indication. Its discovery established the mitochondrial genome as an active source of signaling molecules, a conceptual shift that has already prompted the identification of other mitochondria-derived peptides including humanin and SHLP peptides. These molecules collectively constitute an emerging class, the mitokines, that represent a new category of endogenous regulators of systemic metabolism and aging. MOTS-c is the best-characterized member of this class, and its clinical development will likely inform how the others are approached. [2]

For patients and clinicians engaged with longevity medicine today, MOTS-c occupies a specific and defensible position: an investigational peptide with a coherent mechanism, meaningful preclinical and early human evidence, a favorable short-term safety profile, and a rational dosing framework derived from published research. It is not a panacea, and it is not appropriate for unsupervised self-administration. But for individuals with evidence of metabolic decline, age-related reductions in exercise capacity, or postmenopausal metabolic disruption, a structured MOTS-c protocol administered within a supervised clinical program represents one of the more scientifically grounded options in the current peptide landscape.

The peptide was hiding inside the mitochondrial genome for four billion years of evolution. The cells of a sedentary, aging body produce less of it each year. The question is not whether restoring that signal matters for human healthspan. The question, which the next generation of clinical trials will answer with greater precision, is exactly how, how much, for whom, and for how long.